SCHEMBL17170673

SCHEMBL17170673

CCS(=O)(=O)n1cc(C(=O)C(C)C)c2ccccc21

nearest known ligand 0.57

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.57
HTR3A P46098 2/20 0.49
TSHR P16473 1/20 0.49
LMNA P02545 2/20 0.48
HTT P42858 1/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
PLK1 P53350 1/20 0.45
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.44
HTR6 P50406 4/20 0.43
AKR1C3 P42330 1/20 0.43
AKR1C1 Q04828 1/20 0.43
KAT2B Q92831 1/20 0.43
TNF P01375 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17170675 0.89 ALDH1A1 (0.54) ALDH1A1HTR3ATSHRLMNAHTT
SCHEMBL17170611 0.85 ALDH1A1 (0.56) ALDH1A1HTR3ATSHRLMNAHTT
SCHEMBL17170580 0.84 ALDH1A1 (0.55) ALDH1A1HTR3ATSHRLMNAHTT
SCHEMBL17176299 0.84 SMN1; SMN2 (0.67) ALDH1A1HTR3ALMNASMN1; SMN2PLK1
SCHEMBL15902256 0.83 LMNA (0.46) ALDH1A1HTR3ALMNASMN1; SMN2PLK1
SCHEMBL17170676 0.82 ALDH1A1 (0.52) ALDH1A1HTR3ATSHRLMNAHTT
SCHEMBL17321387 0.78 ALDH1A1 (0.74) ALDH1A1TSHRLMNAHTTSMN1; SMN2
SCHEMBL7719732 0.77 HTR6 (0.55) HTR3AHTR6
SCHEMBL17176587 0.76 SMN1; SMN2 (0.60) ALDH1A1HTR3ALMNAHTTSMN1; SMN2
SCHEMBL17885854 0.75 ALDH1A1 (0.70) ALDH1A1TSHRLMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180072758-A1 5HT3 RECEPTOR ANTAGONISTS TAKEDA CALIFORNIA, INC. 2018-03-15 US disclosed
US-9695195-B2 5-HT3 receptor antagonists TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-07-04 US disclosed
US-9303045-B2 5-HT3 receptor antagonists TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-04-05 US disclosed
US-20150291624-A1 5-HT3 RECEPTOR ANTAGONISTS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-10-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150291624-A1 5-HT3 RECEPTOR ANTAGONISTS HTR3A, HTR5A, HTR3B ALDH1A1 1649/4885HTR3A 1/4885TSHR 313/4885
US-20180072758-A1 5HT3 RECEPTOR ANTAGONISTS HTR3A, HTR3B, HTR5A ALDH1A1 1516/4885HTR3A 1/4885TSHR 289/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.